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Peptidyl-Dipeptidase AAbstract Renin angiotensin system (RAS) is involved in the regulation of cardiovascular homeo-
stasis. Angiotensin (Ang II) is converted from angiotensin I via angiotensin converting enzyme
(ACE). Ang II exerts its effects by binding to two types of receptors; AT1R and AT2R. Ang II effect
on AT1R promotes proliferation, angiogenesis and metastasis in breast tissues. ACE (I/D) polymor-
phism is an insertion/deletion of a 287 bp DNA fragment within intron 16 of ACE gene. A1166C is
a single nucleotide polymorphism (SNP) in the 30-UTR of AT1R gene. Both (D) and (C) alleles were
found to be related to RAS overactivation.
Subjects and methods: One hundred and twenty postmenopausal Egyptian females were included in
the present study and were divided into control group (ﬁfty apparently healthy women) and patients
group (seventy breast cancer patients). Detailed history taking was done with stress on age, family
history, menstrual, obstetric, medical and drug history. Physical examination including body mass
index calculation was done. Histopathological examination was done for tumor grading and
staging. Detection of ACE gene (I/D) polymorphism by PCR and AT1R A1166C SNP using
PCR/RFLP were done.
268 R.M. El Sharkawy et al.Results: A statistically signiﬁcant difference in AT1R A1166C SNP genotype frequencies was
found among the studied groups. The patients group showed higher frequency of ‘‘CC’’ (2.9%
vs 0%) and ‘‘AC’’ (44.3% vs 24%) and lower frequency of ‘‘AA’’ genotype (52.9% vs 76%) than
controls. The patients also showed signiﬁcant higher frequency of allele ‘‘C’’ (25% vs 12%) which
was associated with increased breast cancer risk with an Odds ratio of 2.4444 (95% CI: 1.1967–
4.9931). Testing the dominant model of inheritance revealed a statistically higher frequency of
exposed genotypes ‘‘AC and CC’’ among the patients group (47.1% vs 24%, respectively;
p= 0.013) with substantial increase in breast cancer risk among the exposed genotypes with an
Odds ratio of 2.8243 (95% CI: 1.2679–6.2913). The present study demonstrated that (AC and
CC) genotypes of AT1R A1166C SNP and increased BMI can be considered as predictors for breast
cancer risk among post menopausal Egyptian females. Results also revealed that A1166C SNP of
AT1R gene and ACE/ID polymorphism could not be considered as predictors for breast cancer
prognosis.
ª 2013 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
The Renin angiotensin system (RAS) is critically involved in
the physiological regulation of blood pressure, volume homeo-
stasis and tissue perfusion. It plays an integral role in the path-
ogenesis of hypertension and other cardiovascular diseases.1,2
RAS is now well recognized as a dual vasoactive system, acting
as both a circulating endocrine system and a local tissue
system.3,4
Angiotensin converting enzyme (ACE or Peptidyl-Dipepti-
dase A) is a zinc dependant dipeptidyl carboxypeptidase that
cleaves a dipeptide from the carboxyl terminus of the decapep-
tide Ang I to form Ang II. In addition ACE metabolizes a
number of other peptides, including the vasodilator peptide
bradykinin, to inactive metabolites. Thus, functionally ACE
has a dual enzymatic action resulting in increased vasocon-
striction and decreased vasodilation.5
Ang II is a potent vasoconstrictor which acts by binding to
three recognized angiotensin receptor subtypes, angiotensin
receptor type 1 (AT1R) and the angiotensin receptor type 2
(AT2R), both are structurally similar, and angiotensin receptor
type 4 (AT4R) which is different.
6,7 Binding of Ang II to AT1R
stimulates vasoconstriction, release of aldosterone, angioneog-
ensis, cell growth and proliferation while its binding to AT2R
causes growth inhibition, apoptosis and vasodilatation.7,8
In human, the gene encoding ACE is located on the long
arm of chromosome 17 (17q23). The gene is 21 kilo bases
(kb) long and comprises 26 exons and 25 introns. The most
popular ACE gene polymorphism is an insertion/deletion (I/
D) of a 287-base-pair DNA fragment within the intron 16 of
the ACE gene (NCBI Ref. SNP ID: rs1799752). This polymor-
phism was found to be linked to the ACE activity level which
is doubled in homozygous deletion carriers (DD) when
compared to II carries, while ID carriers show intermediate
activity.9–11
The human AT1R gene is mapped to chromosome 3q21–
q25 and spans more than 55 kb of genomic DNA. A1166C
(NCBI Ref. SNP ID: rs5186) is a single nucleotide polymor-
phism (SNP) in which there is an A/C transversion at position
1166 in the 30 untranslated region (30-UTR) of AT1R gene. It
has been found that the A1166C SNP occurs in a cis-regula-
tory site in the 30-UTR of AT1R gene which after transcription
is recognized by a speciﬁc microRNA (miR-155).9Micro RNAs (miRNAs) are a class of small endogenous
non coding single stranded RNAs (19–24 nucleotides) that
are involved in post transcriptional gene regulation. Micro
RNAs regulate gene expression through binding to their target
messenger RNAs (mRNAs) in the 30-UTR, by a partial
base-pairing mechanism. This binding would result in either
inhibition of translation or induction of target mRNA degra-
dation.11,12 In AT1R gene; the A1166C SNP is considered
one of the miRSNPs (SNP in a micro RNA target site) that
alter a DNA sequence which when transcribed will form a part
of a cis-regulatory site located in the AT1R mRNA 3
0-UTR, at
a site where miR-155 is known to interact. When A allele is
present in this regulatory site, there will be at least seven
consecutive base pair regions of complementarity between
the 50 end of miR-155 and the AT1R mRNA target site, thus
enabling miR-155 to interact with this regulatory site thus
inhibiting AT1R mRNA translation. On the other hand, when
the C-allele is present, base-pairing complementarity is
interrupted, and the ability of miR-155 to interact with the
cis-regulatory site is decreased. As a consequence, miR-155
can no longer attenuate translation, resulting in increased
AT1R densities leading to an increase in RAS activation.
9,11,13
The RAS, in particular the AT1R, is often up-regulated
during the progression from normal to malignant phenotypes,
indicating a possible correlation between the RAS and tumor
progression.14,15 The RAS plays a role in modulation of angi-
ogenesis, cellular proliferation, immune responses, inﬂamma-
tion and extracellular matrix formation. Manipulation of the
RAS may, therefore, provide a safe and inexpensive anticancer
strategy.16–18
In Egypt, breast cancer represents 24% of total cancer cases
(37% in women and 0.8% in men) according to latest records
of Egypt National Cancer Institute (NCI) series of 55,740
patients between 2002 and 2007.17 The three strongest prog-
nostic determinants in operable breast cancer are lymph node
(LN) stage, primary tumor size, and tumor histologic grade,
they were combined in an index termed Nottingham prognos-
tic index (NPI).18
It has been suggested that a positive correlation might exist
between polymorphisms of genes that code for proteins of the
RAS and the risk of developing breast cancer.19,9 So far,
there are no data available in the literature regarding the
association of AT1R receptor (A1166C) and ACE gene (I/D)
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of the study is assessment of these polymorphisms in Egyptian
females with breast cancer.
Aim of the work: Studying any possible association between
the polymorphisms of angiotensin converting enzyme (I/D)
and angiotensin II type I receptor (A1166C) and breast cancer
among post menopausal Egyptian females.
Subjects and methods: After the acceptance of the Ethics
Committee of the Medical Research Institute (MRI), one hun-
dred and twenty Egyptian females were recruited from the out-
patient clinic of the MRI hospital, they were divided as
follows: Group I (control group): It included ﬁfty apparently
healthy postmenopausal Egyptian females without any family
history of breast cancer. Group II (patients group): it included
seventy postmenopausal Egyptian females with breast cancer
with positive family history. Exclusion criteria: patients taking
ACE inhibitors (ACEIs), angiotensin II receptor blockers
(ARBs) or any drugs that affect ACE or angiotensin II level,
patients with history or clinical evidence of any other malig-
nancy and patients with liver, renal and lung diseases.
An informed consent was taken from all subjects included
in this study before its start.
All studied subjects were subjected to the following: Detailed
history taking with special stress on age, age of onset of breast
cancer, family history, menstrual and obstetric history includ-
ing age of menarche, age of menopause, parity, medical his-
tory, drug history especially intake of antihypertensive drugs,
oral contraceptive pills (OCPs) and hormonal replacement
therapy (HRT). Thorough physical examination includingFigure 1 Agarose gel electrophoresis showing (I/D) polymorphisms o
of 190-bp and 490-bp fragments, respectively. Lane A: 100–3000 DNA
Lane F: (II), Lane G: (ID), Lane H: (DD), Lane I: (ID).
Figure 2 Allele speciﬁc ampliﬁcation using insertion-speciﬁc sequenc
lower raws): 100–3000 bp DNA ladder. Lane B (upper raw): II (positi
(upper and lower raws): correctly typed DD.estimation of body mass index (BMI). Histopathological
examination of the breast tissues was done for tumor grading
and histological staging.20,21
Laboratory investigations: After 10 h fasting; ﬁve milliliters
of venous whole blood was withdrawn from each subject and
the following parameters were performed: serum glucose, urea
and creatinine concentrations, serum activity of alkaline pho-
phatase, alanine amino transferase and aspartate amino trans-
ferase were conducted on Olympus AU400 clinical chemistry
analyzer (Beckman Coulter Inc.).22 Serum CA 15.3 was done
on IMMULITE 1000, using a two-step sequential chemilumi-
nescent immunometric assay 23 and molecular studies were
done which included: DNA extraction from peripheral blood
leucocytes, followed by detection of the presence of the (I)
and (D) alleles in the ACE gene by Polymerase chain reaction
(PCR) ampliﬁcation using speciﬁc primers (Forward primer:
50-CTG GAG ACC ACT CCC ATC CTT TCT-30, Reverse
primer: 50-GAT GTG GCC ATC ACA TTC GTC AGA T-
30) followed by agarose gel electrophoresis for the PCR prod-
uct see (Fig. 1). All samples found to be (DD) after ampliﬁca-
tion with the conventional primers, were reampliﬁed using
allele speciﬁc primer pair which recognized insertion speciﬁc
sequences (Forward primer: 50-TGG GAC CAC AGC GCC
CGC CAC TAC-30, Reverse primer: 50-TCG CCA GCC
CTC CCA TGC CCA TAA-30). Allele (Insertion) Speciﬁc
PCR was done to avoid mistyping of the (I) allele as (D) allele
in (ID) heterozygous carriers see (Fig. 2). Detection of AT1R
(A1166C) gene polymorphism using polymerase chain reac-
tion/restriction fragment length polymorphism (PCR/RFLP)f the ACE gene. (D) and (I) alleles were identiﬁed by the presence
ladder, Lane B: (DD), Lane C: (ID), Lane D: (II), Lane E: (DD),
es. The (I) allele produced a 335 bp amplicon. Lane A (upper and
ve control). Lane B (lower raw): ID mistyped as DD. Lanes C–H
850 bp 
PCR
product
Figure 3 PCR product on 2% agarose gel at 850 bp with (100–3000 bp) DNA ladder marker.
Figure 4 Dde I restriction digestion of the PCR product Homozygote (CC) produced three bands (600, 140 and 110 bp long)
homozygote (AA) produced two bands (600 and 250 bp long). Heterozygote (AC) produced all four bands. Lane A: 100–3000 bp DNA
ladder. Lanes B–D, F, G: homozygous (AA). Lane E: homozygous (CC). Lanes H and I: heterozygous (AC).
270 R.M. El Sharkawy et al.technique was done as follows: PCR ampliﬁcation using spe-
ciﬁc primers (Forward primer: 50-AAT GCT TGT AGC
CAA AGT CAC CT-30, Reverse primer: 50-GGC TTT GCT
TTG TCT TGT TG-30) see (Fig. 3), restriction digestion of
PCR products using Dde-I enzyme and agarose gel electropho-
resis of digested PCR products to detect A1166C gene poly-
morphism see (Fig. 4).
2. Statistical analysis24
Statistical analysis was done using SPSS program version 20
(Statistical Package of social sciences, Chicago, USA).25 For
quantitative variables: D’Agostino – Pearson K-squared test
for normality was used to test for the degree of deviation from
normal distribution across all quantitative variables in all
groups and subgroups. For qualitative variables: The data of
the qualitative variables were summarized in the form of fre-
quency or percentages. The Chi-Square test (v2 test) with a
Monte Carlo estimate of the exact p-value, was used to com-
pare proportions of nominal clinical data variables between
groups for 2 by 3 table or more (not for 2 · 2 tables). Chi-
square test was performed only if at least 80% of the cells have
an expected frequency of 5 or greater, and no cell has an
expected frequency smaller than 1. For 2 · 2 tables, Fisher’s
Exact Test was used to compare proportions of nominal clin-
ical data variables. Fisher’s Exact Test can only be applied to 2
by 2 tables whatever the cell values are. For 2 or more by 3 or
more tables with less than 80% of the cells having an expected
frequency of P5, or one or more cells having an expected fre-
quency <1, neither the Chi-square test nor the normal Fisher’s
exact test could be used. In this situation the Freeman–
Halton26 extension of the Fisher’s exact probability test
(Fisher–Freeman–Halton’s test) was used instead. p-Valuesof less than 0.05 was considered a statistically signiﬁcant
difference.
Testing deviation from the HWE is generally performed
using Pearson’s Chi-Squared goodness of ﬁt test, using the
observed genotype frequencies obtained from the data and
the expected genotype frequencies obtained using the HW
equations.27
Odds ratio and risk assessment:28 To measure the effect or
the impact of A1166C AT1R SNP and ACE I/D genotypes
or alleles on the risk of developing breast cancer.
Logistic regression analysis: Used to determine the relation-
ship between predictor variables and a dichotomously coded
dependent variable.29
3. Results
A statistically signiﬁcant difference (p= 0.0211*) in the AT1R
A1166C SNP genotype frequencies between breast cancer
patients and control groups was found. The breast cancer
patients had a higher frequency of the homo-mutant genotype
‘‘CC’’ than controls (2.9% vs 0%), a higher frequency of the
hetero-mutant genotype ‘‘AC’’ than controls (44.3% vs 24%)
and a lower frequency of the homo-wild genotype ‘‘AA’’ than
controls (52.9% vs 76%) (Table 1).
There was a statistically signiﬁcant (p= 0.0134*) difference
in the A1166C AT1R SNP allele frequencies between breast
cancer patients and controls, while the patients had statistically
signiﬁcant higher frequency of the allele ‘‘C’’ than controls
(25% vs 12%) and allele C was associated with a statistically
increased breast cancer risk with an Odds ratio of 2.4444
(95% CI: 1.1967–4.9931) (Table 2).
Testing the recessive model was not applicable due to the
low number of CC genotypes; also the Odds ratio cannot be
Table 1 Comparison of AT1R A1166C SNP genotype frequencies among the studied groups.
A1166C AT1R SNP genotype Control group (n= 50) Patients group (n= 70) Exact p-value
AA (n= 75; 62.5%) 38 (76%) 37 (52.9%) p= 0.021108 *
AC (n= 43; 35.8%) 12 (24%) 31 (44.3%)
CC (n= 2; 1.7%) 0 (0%) 2 (2.9%)
Total (n= 120; 100%) 50 (100%) 70 (100%) 120
Table 2 Comparison of AT1R A1166C SNP allele frequencies among the studied groups.
A1166C alleles Control group (n= 50) Patients group (n= 70) Total Exact p-value Odds ratio (95% CI)
Allele A 88 (88%) 105 (75%) 193 (80.4%) p= 0.0134 * 2.4444 (1.1967–4.9931)
Allele C 12 (12%) 35 (25%) 47 (19.6%)
Total 100 (100%) 140 (100%) 240 (100%)
Table 3 Assessment of the risk of developing breast cancer according to AT1R + A1166C SNP genotypes in different models of
inheritance.
Assumed model
of inheritance
Model
(unexposed vs exposed)
Genotype Control group
n= 50 (100%)
Patients group
n= 70 (100%)
Exact
p-value
Odd’s ratio (95% CI)
aRecessive (AA and AC) vs CC AA and AC 50 (100%) 68 (97.1%) – –
CC 0.0 (0.00%) 2 (2.9%)
bDominant AA vs (AC and CC) AA 38 (76%) 37 (52.9%) 0.013* 2.8243 (1.2679–6.2913)
AC and CC 12 (24%) 33 (47.1%)
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control subjects.
Testing the dominant model of inheritance revealed a statis-
tically higher frequency of exposed genotypes ‘‘AC and CC’’
among the breast cancer patients group when compared to
control group (47.1% vs 24%, respectively; p= 0.013) with
substantial increase in breast cancer risk among the exposed
group ‘‘AC and CC’’ with an Odds ratio of 2.8243 (95% CI:
1.2679–6.2913) when compared to unexposed group ‘‘AA’’
(Table 3). Only BMI and A1166C AT1R SNP genotype were
left as signiﬁcant predictors in this logistic regression model.
The Wald criterion demonstrated that both BMI and
A1166C AT1R SNP genotype made a signiﬁcant contribution
to the prediction of breast cancer risk (p-value = 0.001 and
0.009, respectively) (Table 4).Table 4 Variables included in the ﬁnal logistic regression model wi
Variable Wald
Body mass index (BMI) 11.146
A1166C AT1R SNP genotype (AC and CC versus AA) 6.875
Table 5 Comparison of ACE I/D genotype frequencies among the
ACE I/D genotype Control group (n= 50)
II (n= 21; 17.5%) 8 (16%)
ID (n= 49; 40.8%) 21 (42%)
DD (n= 50; 41.7) 21 (42%)
Total (n= 120; 100%) 50 (100%)No statistically signiﬁcant difference was found (p= 0.940)
in the ACE I/D genotype frequencies between the studied
groups (Table 5). No statistically signiﬁcant difference (Exact
p-value = 0.893, Odd’s ratio = 0.9353 with 95% conﬁdence
interval: 0.5507–1.5886) in the ACE I/D allele frequencies
was found among the studied groups (Table 6).
4. Discussion
Breast cancer accounts for 18% of all female cancers world-
wide and it is one of the main causes of global health burden.
Several environmental, anthropometric, and genetic factors
could contribute to increased risk of breast cancer. A number
of genetic variants have been identiﬁed to be potentially asso-
ciated with breast cancer risk.30th breast cancer risk as the dependent variable.
p-Value Exp (B) 95% CI for Exp (B)
0.001 1.265 (1.102–1.452)
0.009 3.419 (1.364–8.569)
studied groups.
Patients group (n= 70) Exact P-value
13 (18.6%) p= 0.940
28 (40%)
29 (41.4%)
70 (100%) 120
Table 6 Comparison of ACE I/D allele frequencies among the studied groups.
ACE I/D Control group (n= 50) Patients group (n= 70) Total Exact P-value Odds ratio (95% CI)
Insertion (I) 37 (37%) 54 (39%) 91 (38%) 0.893 0.9353 (0.5507–1.5886)
Deletion (D) 63 (63%) 86 (61%) 149 (62%)
Total 100 (100%) 140 (100%) 240 (100%)
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tissue actions involving angiogenesis, cellular proliferation,
apoptosis and inﬂammation. A polymorphic variant composed
of an insertion (I) or a deletion (D) of a 287 base pair insert in
intron 16 (rs: 1799752) has been identiﬁed to be associated with
altered concentration of ACE.31 The DD genotype is associ-
ated with the highest serum levels of the enzyme, the ID geno-
type with the intermediate levels and the II genotype with the
lowest levels.32,33
A1166C is a single nucleotide polymorphism (SNP) in
which there is an A to C transversion at position 1166 in the
30 untranslated region of the AT1R gene. When the C-allele
is transcribed the ability of micro-RNA 155 (miR-155) to
attenuate AT1R mRNA translation is interrupted, resulting
in an overall increase in AT1R density and thus increasing
the biological actions of Ang II resulting in RAS over
activation.34,37
In the present study, the association between ACE I/D and
AT1R A1166C SNP and breast cancer was studied in a sample
of one hundred and twenty Egyptian females divided into two
groups; The control group (Group I) included ﬁfty apparently
healthy postmenopausal Egyptian females without family his-
tory of breast cancer; their mean age was 62.74 ± 5.47 years.
The patient group (Group II) included seventy postmeno-
pausal Egyptian females with breast cancer; their mean age
was 52.1 ± 5.79 years.
Comparing the genotype frequencies of ACE (I/D) poly-
morphism among the studied groups revealed no statistically
signiﬁcant difference (Table 5; p= 0.940) between the control
group (II = 16%, ID = 42%, DD= 42%) and breast cancer
patients group (II = 18.6%, ID = 40%, DD= 41.4%). Fur-
thermore, there was also no statistically signiﬁcant difference
in the allelic frequencies of ACE (I/D) polymorphism between
control group (‘‘I’’ allele = 37%, ‘‘D’’ allele = 63%) and
breast cancer patients group (‘‘I’’ allele = 39%, ‘‘D’’
allele = 61%) (Table 6; p= 0.893, OR= 0.9353; 95% CI:
0.5507–1.5886). The genotype distribution as well as allele fre-
quencies of ACE (I/D) polymorphism were both found to be in
agreement with Hardy–Weinberg equilibrium. Several studies
tried to explore the association between ACE ID polymor-
phism and breast cancer risk; however they revealed conﬂicting
results. Some studies30,35 reported that D allele was positively
associated with breast cancer risk; another study36 reported
that D allele was negatively associated with breast cancer risk;
and others 37 (in agreement with the present study) found no
signiﬁcant difference suggesting that ACE I/D polymorphism
may not be a good predictor for breast cancer risk.
Koh et al.35 ﬁrst studied both I/D and A240T polymor-
phisms of the ACE gene in association with breast cancer, they
found that women with both A and I alleles had a statistically
signiﬁcant reduction of breast cancer risk compared with those
carrying either the TT and/or DD genotypes (the high-activity
genotype) (OR: 0.46; 95% CI: 0.27–0.81). Gonza´lez-Zuloeta
Ladd et al.30 conducted a prospective cohort study to evaluaterelationship of the ACE I/D polymorphism with breast cancer
risk in 4117 Caucasian postmenopausal women. They found
that DD carriers showed a signiﬁcantly increased risk of devel-
oping breast cancer when compared with the II carriers (OR:
1.86; 95% CI: 1.06–3.27). This association remained after per-
forming logistic regression analysis to adjust for other risk fac-
tors, including body mass index, age at menarche, age at
menopause, hormone replacement therapy, and hypertension.
In agreement with the previous studies; Van der Knaap et al.38
found that carriers of the high activity genotype DD had an
increased risk of breast cancer compared with low-activity
II/ID genotype carriers (hazard ratio [HR]: 1.47; 95% CI:
1.05–2.04), but no association was demonstrated for other
cancers.
On the other hand Haiman et al.36 studied ACE I/D poly-
morphisms in relation to breast cancer risk among different
ethnic groups. They found that D allele was reversely associ-
ated with breast cancer risk. (OR: 1.30; 95% CI: 1.05–1.61),
although associations were not entirely consistent across ethnic
groups suggesting that D allele may be a marker of low ACE
levels in some populations, but not all populations.
In agreement with the present study; Sun et al.37 conducted
a recent meta analysis which included four studies (cases: 1422;
controls: 3044), they studied the association between ACE (I/
D) polymorphism and breast cancer. The results of this meta
analysis showed that there was no signiﬁcant difference in
genotype distribution (DD, ID or II) between breast cancer
patients and controls. They suggested that ACE I/D polymor-
phism may not be a genetic risk factor for breast cancer.
These discrepancies in results might be due to insufﬁcient
statistical power and lack of adjustment for other potential
breast cancer confounding factors in some studies, recruitment
procedures of the study population, genetic heterogeneity and
differences in linkage disequilibrium between different popula-
tions as well as environmental backgrounds. Another reason
could be the differences in population characteristics (e.g.,
use of ACE inhibitors and green tea intake39 could inﬂuence
the association between RAS genes and breast carcinogenesis),
these differences in patient characteristics are likely to inﬂu-
ence their phenotypes and may have an impact on the study
results. Using different methods and techniques with different
performance characteristics (e.g., insertion speciﬁc ampliﬁca-
tion to avoid ID mistyping as DD was not done in all studies)
could be another possible reason for result inconsistency.
As for A1166C SNP of AT1R gene, comparing the geno-
type frequencies among the studied groups (Table 1) revealed
a statistically signiﬁcant difference (p-value = 0.0211*)
between control group and breast cancer patients group, where
the breast cancer patients have a higher frequency of the
homozygous mutant genotype (CC) than controls (2.9% vs
0%), a higher frequency of the heterozygous mutant genotype
(AC) than controls (44.3% vs 24%) and a lower frequency of
the homozygous wild genotype (AA) than controls (52.9% vs
76%). Furthermore, there was also a statistically signiﬁcant
Association between the polymorphisms of angiotensin converting enzyme 273difference (p= 0.0134) in the allelic frequencies of A1166C
SNP of AT1R gene between control group and breast cancer
patients group, where the breast cancer patients had a higher
frequency of the mutant allele (C) than controls, and a lower
frequency of the wild allele (A) than controls (OR 2.4444;
95% CI: 1.0616–4.0233) (Table 2). From these results it could
be concluded that the mutant allele (C) was associated with a
statistically signiﬁcant increased risk of developing breast can-
cer. The genotype distribution as well as allele frequencies of
A1166C SNP of AT1R gene were both found to be in agree-
ment with Hardy–Weinberg equilibrium.
Assuming a recessive model of inheritance for AT1R
A1166C SNP; the exposed group is only subjects with the
(CC) genotype while the unexposed group is subjects with both
(AC and AA) genotypes combined. Unfortunately, in the pres-
ent study the Odds ratio involving the (CC) genotype alone
could not be estimated because of the absence of this genotype
among the control subjects. Accordingly assessing the risk in
the recessive model was not possible. Results of the present
study revealed also a statistically higher frequency of exposed
genotypes ‘‘AC and CC’’ among the breast cancer patients
group when compared to control group (p= 0.013) with sub-
stantial increase in breast cancer risk among the exposed group
(AC and CC) with an OR of 2.8243 (95% CI: 1.2679–6.2913)
when compared to unexposed group (AA) (Table 3). This ﬁnd-
ing remains after adjustment for other breast cancer confound-
ing factors, the variables included in the ﬁnal logistic
regression model with breast cancer risk as the dependent var-
iable were BMI (p-value: 0.001, Exp (B): 1.265, 95% CI: 1.102–
1.452) and A1166C AT1R SNP genotype (AC and CC vs AA)
(p-value: 0.009, Exp (B): 3.419, 95%CI: 1.364–8.569) (Table 4).
The ﬁndings of the present study could be explained by the
ability of AT1R A1166C SNP to cause RAS overactivation.
Since A1166C polymorphism occurs in the 30-UTR of the
human AT1R gene, the biological mechanism by which this
SNP could possibly lead to RAS overactivation has been
always questionable. Martin et al.11 and Sethupathy et al.12
demonstrated that A1166C SNP is one of the miRSNPs that
alter a DNA sequence which when transcribed will form a part
of a cis-regulatory site located in the AT1R mRNA 3
0-UTR, at
a site where miRNA ‘‘miR-155’’ is known to interact. When
the (C) allele is present, base-pairing complementarity is inter-
rupted, and the ability of miR-155 to interact with this cis-reg-
ulatory site is decreased. As a consequence, miR-155 can no
longer attenuate translation, resulting in increased AT1R den-
sities leading to an increase in RAS activation.40 Increased
AT1R mRNA transcription was observed in breast cancer cells
when compared to normal cells. This will subsequently lead to
enhanced tumurogenic actions of Ang II on breast cells includ-
ing angiogenesis, cell proliferation, and inﬂammation. Since
AT1R A1166C SNP is known to increase AT1R mRNA
expression, therefore this SNP might be related to increased
AT1R expression in breast cancer cells.
41,42
So far, only limited studies have evaluated the association
between AT1R A1166C SNP and breast cancer risk, yet they
also yielded inconsistent results. Alves Correˆa et al.43 and
Namazi et al.33 suggested that the A1166C polymorphism
was not associated with breast cancer risk (p-values: 0.114
and 0.86, respectively). In contrast, Mendiza´bal-Ruiz et al.44
found that the frequency of (A) allele was higher in breast can-
cer patients group when compared to controls (p= 0.036) and
that the (C) allele carriers had reduced risk of breast cancer(OR: 0.53, p-value = 0.0356). Recently; Xi et al.45 evaluated
the three published studies (235 cases and 601 controls). Signif-
icant association between AT1R A1166C SNP and breast can-
cer risk was observed for (AC) versus (AA) and dominant
model. However, after excluding one study that was not in
Hardy–Weinberg equilibrium (by Alves Correˆa et al.43, this
association disappeared while a marginally signiﬁcant associa-
tion was observed for CC versus AA (OR= 0.31, 95% CI
0.10–0.99). Since publication bias was not assessed for these
ﬁndings; they recommended further studies to explore the
association between this SNP and breast cancer risk.
From the previously mentioned studies, only limited data
are available regarding the association between AT1R
A1166C SNP and breast cancer risk. Lack of consistency in
the ﬁndings, limited sample size, insufﬁcient statistical power
for one study as well as paucity of explanations for the
observed associations could be noticed. Further large popula-
tion based studies are still needed to get a conclusive evidence
about the association between AT1R A1166C SNP and the
risk of breast cancer, as well as AT1R expression in breast can-
cer tissues in relation to this SNP genotype.
In conclusion, the present study demonstrated that (AC
and CC) genotypes of AT1R A1166C SNP together with
increased BMI can be considered as signiﬁcant predictors for
breast cancer risk among post menopausal Egyptian Females.
Results also revealed that A1166C SNP of AT1R gene and
ACE/ID polymorphism might not be a good predictor for
breast cancer prognosis. Also, pharmacological inhibition of
the angiotensin II carcinogenic effect through inhibition of
AT1R together with weight reduction could be used to delay
or prevent the occurrence of breast cancer in post menopausal
females, although more detailed trials and experiments are
required to conﬁrm this conclusion.Conﬂict of interest
None.
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